Somatic alterations frequently implicated in de novo AML, including FLT3, NPM1, and DNMT3A, are frequently not mutated, instead genes involved in the spliceosome modulator SRSF2 and in the epigenetic regulation of DNA, including IDH1/2, TET2, ASXL1, and EZH2 are mutated in bast phase MPN. The gene discussed is DNMT3A; the disease is myeloproliferative disorder.